Please login to the form below

Not currently logged in
Email:
Password:

advanced breast cancer

This page shows the latest advanced breast cancer news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Keytruda and microbiome synergy, Pfizer's files PARP contender and more

Daily Brief: Keytruda and microbiome synergy, Pfizer's files PARP contender and more

breast cancer (MBC), with the EMA also accepting the filing. ... In January, Lynparza became the first of the class to gain approval in breast cancer, with ovarian cancer being the primary focus for the competitors.

Latest news

  • FDA backs earlier use of Lilly’s breast cancer drug Verzenio FDA backs earlier use of Lilly’s breast cancer drug Verzenio

    negative metastatic breast cancer, ”said Joyce O'Shaughnessy, chair of the breast cancer research programme for Baylor University Medical Center, in a press release. ... This information will help inform treatment decisions for each patient, which can

  • AZ and Merck & Co get FDA breast cancer nod for Lynparza AZ and Merck & Co get FDA breast cancer nod for Lynparza

    AstraZeneca and Merck &Co have been awarded FDA approval for Lynparza in BRCA-positive advanced breast cancer - the first drug in the PARP inhibitor class to be approved outside ovarian cancer. ... The drug can also be used in hormone receptor-positive

  • Novartis bags new breakthrough status for Kisqali in breast cancer Novartis bags new breakthrough status for Kisqali in breast cancer

    The BTD is based on the results of the MONALEESA-7 trial, which involved pre-menopausal women with hormone-receptor positive, HER2-negative advanced breast cancer and was the first to ... If approved in younger women with advanced breast cancer, Kisqali

  • NICE set to reject wider use of Eisai’s Halaven NICE set to reject wider use of Eisai’s Halaven

    The UK health technology assessment agency says there is a lack of evidence that Halaven offers value for money in locally-advanced or secondary breast cancer in patients who have previously ... Advanced breast cancer patients are generally offered an

  • NICE backs two advanced breast cancer drugs after price cuts NICE backs two advanced breast cancer drugs after price cuts

    NICE backs two advanced breast cancer drugs after price cuts. An estimated 8, 000 women will be eligible to receive the drugs due to discounts. ... important breakthroughs for women with advanced breast cancer in the last two decades”.

More from news
Approximately 1 fully matching, plus 144 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... Tucatinib is currently being

  • Digital disruption Digital disruption

    Targeting advanced breast cancer the partners will combine real-world patient data and cognitive computing to ‘optimise cancer care and improve outcomes’. ... Next, they draw in the basic signalling pathways that can go wrong in cancer cells.

  • Deal Watch August 2016 Deal Watch August 2016

    The lead product is talazoparib, a PARP inhibitor, bought from BioMarin in phase III for treatment of BRCA mutated advanced breast cancer. ... This would complement Pfizer's palbococlib, launched in the US in February 2015, to treat HR+/HER2 metastatic

  • Pharma deals during July 2014 Pharma deals during July 2014

    Seragon's focus is in hormone dependent cancers and specifically the development of its Selective Estrogen Receptor Degrader (SERD) platform of oral, small molecule therapeutics for breast and other cancers. ... The lead SERD compound, ARN-810, is

  • Pharma deals during August 2013 Pharma deals during August 2013

    To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic ... Palbociclib, which is the result of an early

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

  • FALCON trial of fulvestrant for advanced breast cancer

    FALCON trial of fulvestrant for advanced breast cancer. The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer. ... In the interview, he explains that the study was designed to address the

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics